SecBot SecBot

IDYA

IDEAYA Biosciences, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001676725 Biotech & Drug Discovery
$30.36 −1.47 (−4.62%)
Nov 16 4:00 PM ET · prev $31.83
Market cap
$3.0B
Mid cap
Consensus
Buy
91% Buy or better · 22 analysts
Median target
$51.00
+68% · range $30.00–66.00
1 year
−8.9%
from $33.34 · Nov 17
30 days
−10.2%
from $33.81
52-week range
$27.60–42.48
−29% from high · low Jun 10
Avg volume 20D
1.06M
shares / day
Short interest
8.24M
≈8.5% of shares · −9.3%
Days to cover
8.9
at average volume
Insider net
+$280.4K
1 buyer · 2 sellers · 12 mo
New fund stakes
3
Q2 2026 13F · 1 exit
Filing reports
13
analyzed by SecBot
SecBot read BEARISH 3 reports · 90 days
Balance 1 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 1/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    1 insider bought $1.6M at an average $32.96. 2 insiders sold $1.4M. Price is 8% below their cost.

  • InstitutionsMIXED

    Q2 2026: 20 added (3 new), 18 trimmed or exited. Largest new: Arrowstreet Capital, Limited Partnership $33.2M, Walleye Capital $14.4M.

  • AnalystsBULLISH

    20 of 22 rate it Buy or better. Median target $51.00 (+68%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$1.133 → −$1.159 over 90 days. 2 up, 7 down in 30 days.

  • Short sellersSTEADY

    Short interest −9.3% to 8.24M shares. 8.9 days to cover, ≈8.5% of shares.

  • TrendDOWNTREND

    14% below its 50-day average.

Who's buying

13F· Q2 2026
3
new positions
1
exit
$61.4M
in new stakes
FundMoveSharesValue
BAKER BROS. ADVISORS LPADD5,010,030$186.7M
PRICE T ROWE ASSOCIATES INC /MD/ADD2,207,451$82.3M
ALLIANCEBERNSTEIN L.P.DOUBLED1,627,521$54.2M
Fiera Capital CorpTRIM1,445,885$53.9M
FEDERATED HERMES, INC.TRIM1,431,630$53.4M
GOLDMAN SACHS GROUP INCTRIM1,231,614$45.9M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPNEW891,608$33.2M
Nuveen, LLCADD640,257$23.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

22 analysts
Buy 91% rate it Buy or better
Strong Buy8Buy12Hold2Sell0Strong Sell0
12-month targets · 13 analysts

Price is inside the target range. Median implies +68%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 10, 2026Mizuho
MAINTAIN
MAINTAINOutperform
Nov 5, 2026Citigroup
MAINTAIN
MAINTAINBuy
Nov 4, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Nov 4, 2026Truist Securities
REITERATE
REITERATEBuy
Nov 4, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Nov 4, 2026Wedbush
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$1.6M
bought · 1 insider
$1.4M
sold · 2 insiders
−7.9%
vs their $32.96 cost
DateInsiderTypeValue
Oct 6, 2026
Hata Yujiro S
President and CEO
Oct 6, 2026
SELL$954.8K
Oct 6, 2026
Hata Yujiro S
President and CEO
Oct 6, 2026
EXERCISE$113.5K
Oct 6, 2026
Hata Yujiro S
President and CEO
Oct 6, 2026
SELL$30.6K
Jul 7, 2026
Ruiz Briseno Andres
Chief Accounting Officer
Jul 7, 2026
EXERCISE$122.8K
Jul 7, 2026
Ruiz Briseno Andres
Chief Accounting Officer
Jul 7, 2026
SELL$382.1K
Jun 16, 2026
Hampton Malcolm Garret
Director
Jun 16, 2026
AWARD20,000 sh
Jun 16, 2026
Stein Jeffrey
Director
Jun 16, 2026
AWARD20,000 sh
Jun 16, 2026
ROSEN TERRY J
Director
Jun 16, 2026
AWARD20,000 sh

Earnings setup

Estimates
−$1.16
EPS estimate, this quarter
−2%
estimate change, 90 days
2↑ 7↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.16-$1.47–-$0.83-3.7%$20.1M
Next Q-$1.24-$1.41–-$1.04-7.4%$9.2M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
8,236,480
shares short
-9.3%
vs prior settlement
8.9
days to cover
≈8.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 4, 2026 Other
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a
Nov 3, 2026 SEC
Four institutional asset managers added to their IDYA positions in Q3 2026, collectively increasing holdings by $3.3M…
INST-CLUSTER · Impact 3/10
Nov 3, 2026 SEC
The company completed its NDA submission for darovasertib in metastatic uveal melanoma and announced the closure of…
8-K · Impact 5/10
Oct 6, 2026 SEC
CEO Yujiro Hata filed a Form 144 notice of intent to sell shares of IDEAYA Biosciences, covering 8,804,981 shares…
144 · Impact 6/10
Oct 6, 2026 Insider
Hata Yujiro S sold 25,538 shares
President and CEO @ $37.39 ($954.8K)
Oct 6, 2026 Insider
Hata Yujiro S acquired via exercise 26,338 shares
President and CEO @ $4.31 ($113.5K)
Oct 6, 2026 Insider
Hata Yujiro S sold 800 shares
President and CEO @ $38.26 ($30.6K)
Jun 30, 2026 Inst.
BAKER BROS. ADVISORS LP · ADD
5,010,030 shares ($186.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 4, 2026
Press release
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed…
Nov 1, 2026
Trial readout
T-90d Trial Readout: IDE196 (Phase 3)
Trial: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Sponsor: IDEAYA Biosciences Phase…
Nov 2, 2026
Earnings date
IDYA Q3 2026 Earnings Scheduled · 2026-11-02
Oct 30, 2026
Press release
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed…
Oct 25, 2026
Trial readout
T-90d Trial Readout: IDE196 (Phase 3)
Trial: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Sponsor: IDEAYA Biosciences Phase…

SecBot reports

13 filings · 1 bullish · 4 bearish · 1 mixed · 7 neutral
All IDYA filing & press-release reports (13)